Uptake of genetic counseling and multi‐gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing. Issue 2 (27th September 2021)

• Record Type: Journal Article
• Authors: Mooney, Ryan; Espinel, Whitney; Elrick, Ashley; Kehoe, Kelsey; Kohlmann, Wendy; Kaphingst, Kimberly A.
• Is Part Of: Journal of genetic counseling. Volume 31:Issue 2(2022)
• Page Start: 470
• Page End: 478
• Publication Date: 2021-09-27
• Subjects: genetic counseling -- genetic testing -- genetics services -- hereditary breast and ovarian cancer -- multi‐gene panel; Genetic counseling -- Periodicals; 616.042
• DOI: 10.1002/jgc4.1513
• Languages: English
• ISSNs: 1059-7700

Abstract

Abstract: Women with a personal history of breast or ovarian cancer who previously had BRCA1 / 2 testing now have the opportunity for additional genetic risk information through multi‐gene panel testing. However, little is known about women's receptivity to further contact and uptake of genetic counseling and updated genetic testing. Utilizing a clinic database to identify potential participants, we prospectively contacted women in the United States with a personal and/or family history of breast or ovarian cancer who had negative BRCA1 / 2 testing, which was performed primarily between 2011 and 2018. Eligible and interested participants were scheduled for a genetic counseling appointment to discuss updated genetic testing using a multi‐gene panel. We attempted to contact 455 participants, screened 203 (45%), and 103 (23%) completed a pre‐test genetic counseling visit to discuss updated testing. Of these, 88 participants had updated multi‐gene panel testing. Participants had an average age of 59 years, and most (78%) had breast cancer with an average age of 45 at diagnosis. The majority (97%) of participants were white. Of participants who underwent panel testing, 13% ( n = 11) had at least one pathogenic variant identified. Most participants (86%) had an out‐of‐pocket cost of $100 or less for their panel. There is a sizable population of women with a personal and/or family history of breast or ovarian cancer and negative BRCA1 / 2 test results who would qualify for updated multi‐gene panel testing. In our study, 59% of those reached who were eligible completed a pre‐test genetic counseling visit. Clinics could consider an outreach program to offer genetic counseling and updated genetic testing. Supports for this type of effort may include coordinators and genetic counseling assistants and an available database with patients' contact information and prior genetic test results. Updated testing allows women more information about their risk and may expand the value of genetic counseling.